Jamieson, StephenBrooke, DarbyHeinrich, DAtwell, GJSilva, SHamilton, EJTurnbull, APRigoreau, LJTrivier, ESoudy, CSamlal, SSOwen, PJSchroeder, ERaynham, TFlanagan, JackDenny, William2017-07-142012Journal of Medicinal Chemistry 55(17):7746-7758 20120022-2623http://hdl.handle.net/2292/34225A high-throughput screen identified 3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic acid as a novel, highly potent (low nM), and isoform-selective (1500-fold) inhibitor of aldo-keto reductase AKR1C3: a target of interest in both breast and prostate cancer. Crystal structure studies showed that the carboxylate group occupies the oxyanion hole in the enzyme, while the sulfonamide provides the correct twist to allow the dihydroisoquinoline to bind in an adjacent hydrophobic pocket. SAR studies around this lead showed that the positioning of the carboxylate was critical, although it could be substituted by acid isosteres and amides. Small substituents on the dihydroisoquinoline gave improvements in potency. A set of "reverse sulfonamides" showed a 12-fold preference for the R stereoisomer. The compounds showed good cellular potency, as measured by inhibition of AKR1C3 metabolism of a known dinitrobenzamide substrate, with a broad rank order between enzymic and cellular activity, but amide analogues were more effective than predicted by the cellular assay.Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher.https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htmJournal Article10.1021/jm3007867Copyright: American Chemical Society22877157http://purl.org/eprint/accessRights/RestrictedAccess1520-4804